Physician profile
Christopher Tait
NPI 1083064224
$1,976.78
in general payments reported to CMS, 2019-2025
21 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.21 · 2020: $43.66 · 2021: $128 · 2023: $200 · 2024: $332 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,787.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $274.53 | 2020-2025 | Viberzi, Linzess, Creon |
| Gilead Sciences, INC. | $226.07 | 2021-2024 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.55 | 2024-2025 | Xifaxan |
| Genzyme Corporation | $196.22 | 2025 | |
| Madrigal Pharmaceuticals | $188.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $166.67 | 2020-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $120.51 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $96.46 | 2021-2025 | Entyvio |
| Pfizer INC. | $88.09 | 2024-2025 | |
| Ardelyx, INC. | $87.52 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $66.37 | 2024-2025 | Injectafer |
| Aimmune Therapeutics, INC. | $39.31 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $34.74 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $32.01 | 2024 | Rebyota |
| Laborie Medical Technologies Corp. | $31.79 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pentax of America, INC. | $31.73 | 2023 | |
| Sanofi Pasteur INC. | $20.67 | 2025 | |
| Lilly USA, LLC | $19.97 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $18.99 | 2024 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $18.18 | 2025 | Iqirvo |
| Organon LLC | $17.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Tait listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.